Assistant Professor of Pediatrics and faculty member of Medical Genetics Tsui-Fen Chou, Ph.D., is credited for her role in the early stage development of molecule CB-5083 which will be a lead drug candidate in patients with relapsed and refractory multiple myeloma. Phase 1 clinical testing has already begun.
CB-5083 came out of DBeQ and ML240, which Dr. Chou developed in collaboration with the NIH MLPCN program when she was a postdoctoral fellow. Cleave Biosciences took her ML240 scaffold, made a few chemical modifications to it, to enhance potency and reduce metabolism, to generate CB-5083.
In a press release from Cleave Biosciences, Dr. Chou is credited as a discovery partner of CB-5083.
Raymond Deshaies, PhD, founder of Cleave Biosciences, credits Dr. Chou and her involvement with the creation of CB-5083. "It's a...